Major Shareholder Exits Ventyx Biosciences Following Eli Lilly Merger Completion
Summary
A significant beneficial owner, Somasundaram Subramaniam and affiliated entities, has fully exited their position in Ventyx Biosciences, Inc. following the company's merger with Eli Lilly and Company.
Key Events · Ownership and Investor Activity · VTYX
-
Major Shareholder Exit
Somasundaram Subramaniam and affiliated entities, previously a beneficial owner of more than five percent, have ceased to own any securities of Ventyx Biosciences, Inc.
-
Merger-Driven Disposition
The disposition of shares occurred on March 4, 2026, as a direct consequence of the completed merger between Ventyx Biosciences, Inc. and Eli Lilly and Company.
-
Cash Conversion
All beneficially owned shares were converted into the right to receive $14.00 per share in cash, less any applicable tax withholding, at the effective time of the merger.
-
Prior Share Distribution
Prior to the merger, on February 27, 2026, 474,632 shares held by NSV Partners III, L.P. and 220,086 shares held by New Science Ventures, LLC were distributed pro rata for no consideration.
Analysis · VTYX · Life Sciences
This Schedule 13D/A filing confirms that Somasundaram Subramaniam and associated entities, previously a significant beneficial owner, no longer hold any securities in Ventyx Biosciences, Inc. This exit is a direct result of the company's merger with Eli Lilly and Company, which was completed on March 4, 2026. All beneficially owned shares were converted into cash at $14.00 per share. While the merger itself was the primary market-moving event, this filing provides a formal update on the final disposition of shares by a major investor group.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTYX was trading at $13.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.